Who we are

"We help save lives"

Who we are

06/10/2019 Farmacéuticos 0

Genbie SAS (Genbie) 

It is one of the youngest biopharmaceutical companies with a projection of high profitability and rapid growth in Colombia, with several products in process, oncological medicines for different applications, which makes us a promising player in the generic drugs against cancer.

In addition to the field of oncology, we are also venturing into multiple sclerosis, immunosuppressants and specialized antibiotics.

Genbie’s business focuses on the import and commercialization of innovative bio-Generic products, Immunomodulators, biosimilars, as well as innovative biological products.

Recently in the Colombian legal system (2016), the Ministry of Health and Social Protection (MSPS) established a specific regulatory system reduced for “the sanitary registration of new (pioneer) and known biological drugs (biocompetitors, biosimilares or biogenerics)”.

The decrease of regulatory barriers and the approval of recent measures in favor of the entry of biosimilar or biogeneric products of biological products has allowed Colombia to allow the development of biocompetidores in the quest to reduce the high expenses for the government, reason for which Genbie wants to be a leader and a reference in this new path and to contribute widely in the sustainability of the health system.

Genbie is a pharmaceutical company based in Bogotá – Colombia.

It specializes in providing specialized medicines of the highest quality imported from all over the world, particularly in countries with the highest quality standards.

With a focus on product quality and operational flexibility, our firm brings decades of experience in the pharmaceutical Industry from its shareholders and founders.

Our objective is clear

Provide innovative solutions at lower cost to patients, the medical community and health care providers in a cost-effective and quality way.

We achieve this through a relentless focus on quality standards and putting the interest of patients first.

 

Leave a Reply